Compound class:
Synthetic organic
Comment: BB2-50F is a 6-substituted 5-(N,N-hexamethylene)-amiloride (HMA) derivative that was first described as an inhibitor of human urokinase-type plasminogen activator [2].
The compound also has antibacterial activity and has been shown to be a dual inhibitor of mycobacterial F1F0-ATP synthase and succinate dehydrogenase [1]. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
In mycobacteria, BB2-50F targets the membrane-embedded c-ring of F1F0-ATP synthase and the catalytic subunit of succinate dehydrogenase [1]. Treatment with BB2-50F induces metabolic and respiratory dysregulation and reactive oxygen species (ROS) production. |